Micronization is important in the early stages of the pharmaceutical manufacturing process – reducing the particle size of an ingredient through jet milling can help enhance dissolution and improve bioavailability of difficult to process Active Pharmaceutical Ingredients (API).
However, challenges such as poor powder flow and high static can reduce process efficiencies and present difficulties for downstream formulation.
Microsize and Grace conducted a series of experiments to evaluate the impact of SYLOID® mesoporous silica on mill retention, yield rate, powder flow and static properties.
Download the case studies and discover how to optimize your micronization processes, including:
For this experiment, the active ingredient used was Cholesterol, a waxy solid that is difficult to process, akin to the physical properties of many complex small molecules. Different concentrations of SYLOID® mesoporous silica were added to Cholesterol, which was then micronized in a jet mill.
Download your copy of the case study today to discover how both run time and yield rates significantly improves with low level percentage additions of SYLOID® mesoporous silica.
For this experiment, Acetaminophen and Ibuprofen were selected to study their powder flow properties before and after micronization with the addition of different levels of SYLOID® 244 FP mesoporous silica.
Download your copy of the case study today to discover how low percentage additions of SYLOID® 244 FP mesoporous silica can impart substantial benefits to the physical properties of micronized APIs, making downstream blending and formulation easier.
Follow us to keep up-to-date on new products, industry events, and the latest insights from our technical experts.
© 2025 W. R. Grace & Co.-Conn.
7500 Grace Drive Columbia, MD 21044